Inclusion Criteria:

        Subjects must satisfy the following criteria to be enrolled in the study:

          1. Subject is a male ≥ 18 years of age at the time of signing the informed consent form
             (ICF).

          2. Subjects must have histologically or cytologically confirmed adenocarcinoma of the
             prostate.

          3. Subjects must have documented progressive metastatic castration-resistant prostate
             cancer (CRPC).

          4. Subjects must have progressed on androgen deprivation therapy (ADT) and at least one
             prior secondary hormonal therapy approved for CRPC (eg, abiraterone, enzalutamide,
             apalutamide, or darolutamide).

          5. Subjects must have serum testosterone ≤ 50 ng/dL. Subjects must continue primary
             androgen deprivation with a luteinizing hormone-releasing hormone (LHRH) analogue
             (agonist or antagonist) if they have not undergone bilateral orchiectomy.

          6. Subjects must have discontinued bicalutamide ≥ 6 weeks prior to the first dose of
             CC-94676. Subjects must have discontinued abiraterone, rucaparib, or olaparib ≥ 2
             weeks prior to the first dose of CC-94676. Subjects must have discontinued
             enzalutamide, flutamide, nilutamide, and other approved secondary hormonal therapy,
             chemotherapy, immunotherapy, or investigational treatments (except treatments to
             maintain castrate status) > 4 weeks prior to the first dose of CC-94676.

        Exclusion Criteria:

        The presence of any of the following will exclude a subject from enrollment:

          1. Subject has confirmed or suspected small cell carcinoma of the prostate/neuroendocrine
             prostate cancer.

          2. Subject currently has symptomatic brain or epidural central nervous system (CNS) or
             spinal metastases requiring steroids (above physiologic replacement doses) or
             radiation.

          3. Subject had palliative radiation, strontium-89, or radium-223 ≤ 4 weeks prior to the
             first dose of CC-94676. Palliative radiation for the alleviation of pain due to bone
             metastasis will be allowed during the study, as long as this is not a sign of
             clinically significant disease progression.

          4. Subject has any significant medical condition, such as uncontrolled infection,
             laboratory abnormality, or psychiatric illness that would prevent the subject from
             participating in the study.